Evidence map›Paper›PMID 35268797›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis and Biological Evaluation of 1-(2-(6-Methoxynaphthalen-2-yl)-6-methylnicotinoyl)-4-Substituted Semicarbazides/Thiosemicarbazides as Anti-Tumor Nur77 Modulators.

Hongyu Hu, Jiangang Huang, Yin Cao, Zhaolin Zhang, Fengming He, Xianfu Lin, Qi Wu, Shengxian Zhao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hongyu HuDepartment of Chemistry, Zhejiang University, Hangzhou 310027, China.
Jiangang HuangSchool of Pharmaceutical Sciences, Xiamen University, South Xiang-An Road, Xiamen 361102, China.
Yin CaoSchool of Pharmaceutical Sciences, Xiamen University, South Xiang-An Road, Xiamen 361102, China.
Zhaolin ZhangXingzhi College, Zhejiang Normal University, Lanxi 321004, China.
Fengming HeSchool of Pharmaceutical Sciences, Xiamen University, South Xiang-An Road, Xiamen 361102, China.
Xianfu LinDepartment of Chemistry, Zhejiang University, Hangzhou 310027, China.
Qi WuDepartment of Chemistry, Zhejiang University, Hangzhou 310027, China.
Shengxian ZhaoCollege of Science and Technology, Ningbo University, Cixi 315302, China.ORCID 0000-0003-1776-4624
Xiamen University · CNNingbo University · CNZhejiang University · CNZhejiang Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nur77 is an orphan nuclear receptor that participates in the occurrence and development of a variety of tumors. Many agonists of Nur77 have been reported to have significant anticancer effects. Our previous studies have found that the introduction of bicyclic aromatic rings, such as naphthalyl and quinoline groups, into the

Indexed as

Antineoplastic AgentsApoptosisCell ProliferationNuclear Receptor Subfamily 4, Group A, Member 1SemicarbazidesCell Line, TumorDrug Screening Assays, AntitumorHumansMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsNR4A1 protein, humanNuclear Receptor Subfamily 4, Group A, Member 1Semicarbazidesthiosemicarbazideanti-tumor activityapoptosisNur77semicarbazidethiosemicarbazide

Identifiers

PMID35268797
PMCPMC8911927
OpenAlexW4220745303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.